medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2011, Número 12

<< Anterior

Ginecol Obstet Mex 2011; 79 (12)


Conclusiones del Consenso para la prevención del cáncer cervicouterino en México

Idioma: Español
Referencias bibliográficas: 24
Paginas: 816-818
Archivo PDF: 152.99 Kb.


FRAGMENTO

El cáncer cervicouterino es una enfermedad prevenible, detectable y, generalmente, curable si se diagnostica en sus estadios iniciales. La disminución de su mortalidad a partir de la introducción de la citología de Papanicolaou es buena muestra de ello. Una tasa nacional elevada de mortalidad por cáncer cervicouterino es no sólo un fracaso de los sistemas de salud sino una tragedia económica, familiar y afectiva que refrenda las evidencias de una inequidad social.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Monk BJ, Herzog TJ. The evaluation of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination. Amer J Obstet Gynecol doi:10.1016/j.ajog.2007.08.030

  2. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. New Engl J Med 2005;353:2101-2104

  3. Parikh S, Brennan P, Boffetta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003;105:687-691

  4. Modificación a la Norma Oficial Mexicana NOM-014- SSA2-1994, Para la prevención, detección, diagnóstico, tratamiento, control y vigilancia epidemiológica del cáncer cérvico uterino. Diario Oficial de la Federación. 31 de mayo de 2007

  5. Koutsky LA, for the FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions, New Engl J med 2007;356:1915-1927

  6. Paavonen J, Naud P, Salmeron J. Efficacy of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA):final analysis of a double-blind, randomised study in young women. Lance 2009;374:301.314

  7. Crosbie EJ, Brabin L. Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. BJOG 2010;117:137-142

  8. Bauch CT, Li M, Chapman G , et al. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? Lancet Inf Dis 2010;10:133-137

  9. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009;151:538-545

  10. Kreimer AR, Rodriguez AC, Hildelsheim A , et al. Proofof-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2001;103:1444-1451

  11. Pagliusi SR, Teresa Am. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-578

  12. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003;9:37-48

  13. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries – Key challenges and issues. New Engl J med 2007;356:1908-1910

  14. Andrus JK, Sherris J, Fitzsimmons JW , et al. Introduction of human papillomvirus vaccines into developing countries – International strategies for funding and procurement. Vaccine 2008;26S:K87-K92

  15. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologists 2005;10:528-538

  16. Human papillomavirus vaccination practices: A survey of US physicians 18 months after licensure. Pediatrics 2010;128:425-433

  17. Harper DM., Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8:1663-1679

  18. Citología para VPH +

  19. Insisgna RP, Glass Ag, Rush BB. Diagnoses and outcome in cervical cancer screening: a population based study. Am J Obstet Gynecol 2004;191:105-113

  20. Strander B, Andersson-Ellström A, Milson I , et al. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population based cohort study. BMJ 2007;335:1077- 1083

  21. Jakobson M, Gissler M, Paavonen J , et al. Long-term mortality in women treated for cervical intraepithelial neoplasia. BJOG 2009;116:838-84

  22. Elfgren K, Jacobs M, Walboomers JM , et al. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002;100:965-971

  23. Garland AM. Can we really beat cervical cancer? Med J Australia 2003;178:647-650

  24. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human papillomavirus infection and vaccination – Implications for second generation vaccines. Vaccine 2008;26S:S62-S67




2020     |     www.medigraphic.com